1 esis of asthma (eg, omalizumab, mepolizumab, reslizumab).

2 designed to neutralize IL-5 (mepolizumab and reslizumab).

3 assigned (1:1) to receive either intravenous reslizumab (3.0 mg/kg) or placebo every 4 weeks for 1 ye

4          We sought to evaluate the effect of reslizumab, a neutralizing antibody against IL-5, in chi

5 , 67%, 64%, and 24% in the 1, 2, and 3 mg/kg reslizumab (all P < .001) and placebo groups, respective

6 sessment scores; the differences between the reslizumab and placebo groups were not statistically sig

7                              Safety data for reslizumab, another anti-IL-5 monoclonal antibody, and b

8 dy 1; 119 [51%] for placebo and 67 [29%] for reslizumab for study 2), upper respiratory tract infecti

9                          One patient in each reslizumab group and 2 in the placebo group had serious

10                          Two patients in the reslizumab group had anaphylactic reactions; both respon

11        The most common adverse events in the reslizumab groups were headache, cough, nasal congestion

12          In both studies, patients receiving reslizumab had a significant reduction in the frequency

13             These results support the use of reslizumab in patients with asthma and elevated blood eo

14 e aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, mod

15 toms (127 [52%] for placebo and 97 [40%] for reslizumab in study 1; 119 [51%] for placebo and 67 [29%

16                                              Reslizumab is a humanised anti-interleukin 5 monoclonal

17 953 were randomly assigned to receive either reslizumab (n=477 [245 in study 1 and 232 in study 2]) o

18 nt received a specific volume of study drug (reslizumab or matching placebo) on the basis of the pati

19 ned to receive infusions of 1, 2, or 3 mg/kg reslizumab or placebo at weeks 0, 4, 8, and 12.

20                                              Reslizumab significantly reduced intraepithelial esophag

21                     Common adverse events on reslizumab were similar to placebo.

22  New anti-IL-5 therapeutics, mepolizumab and reslizumab, were US Food and Drug Administration approve